Action Acurx Pharmaceuticals - ACXP

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

0,865

Prix Achat

0,8501

Prix Vente

0,865

Volume échangé

54 672

0,8501 Fourchette du Jour 0,894

0,72 Plage de 52 semaines 5,28

Cap du marché

14,612M

Clôture Veille

0,894

Ouverture

0,893

Dernière Transaction

100

0.865

Dernière heure de transaction

18:01:14

Volume financier

US$ 47 289

VWAP

0,864963

Volume moyen (3 m)

129 627

Actions en circulation

16 892 548

Rendement du Dividende

Ratio Cours sur Bénéfices

-1,00

Bénéfice par action (BPA)

-0,86

Chiffre d'affairess

Bénéfice net

-14,58M

Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.

Secteur

Pharmaceutical Preparations

Industrie

Pharmaceutical Preparations

Site Web

www.acurxpharma.com

Siège social

Wilmington, Delaware, USA

Fondé

Acurx Pharmaceuticals Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker ACXP. Le dernier cours de clôture d'Acurx Pharmaceuticals était de US$0,89. Au cours de la dernière année, les actions de Acurx Pharmaceuticals ont été négociées dans une fourchette de prix de US$ 0,72 à US$ 5,28.

Acurx Pharmaceuticals compte actuellement 16 892 548 actions en circulation. La capitalisation boursière d'Acurx Pharmaceuticals est de US$15,10 million. Acurx Pharmaceuticals a un ratio cours/bénéfice (ratio PE) de -1.00.

Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA Communications

Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA Communications PR Newswire STATEN ISLAND, N.Y., Dec. 9, 2024 Following the previously...

Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset

Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset PR Newswire STATEN ISLAND, N.Y., Nov. 20, 2024 STATEN ISLAND, N.Y., Nov. 20, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc...

Form 8-K - Current report

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update PR Newswire STATEN ISLAND, N.Y., Nov. 13, 2024 STATEN ISLAND, N.Y., Nov. 13, 2024 /PRNewswire/ -- Acurx...

Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference

Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference PR Newswire STATEN ISLAND, N.Y., Oct. 21, 2024 The...

Acurx Pharmaceuticals Announces Participation at The Spartan Capital Investor Conference to Showcase Growth Companies and Foster High-Level Investor Engagement

Acurx Pharmaceuticals Announces Participation at The Spartan Capital Investor Conference to Showcase Growth Companies and Foster High-Level Investor Engagement PR Newswire STATEN ISLAND, N.Y...

Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024

Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024 PR Newswire STATEN ISLAND, N.Y., Oct. 16, 2024 STATEN ISLAND, N.Y., Oct. 16, 2024 /PRNewswire/ -- Acurx...

Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues

Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues PR Newswire STATEN ISLAND, N.Y., Sept. 26, 2024 New analyses...

Acurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile Symposium

Acurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile Symposium PR Newswire STATEN...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0.075	9.49367088608	0.79	0.927	0.79	46759	0.86942736	CS
4	-0.415	-32.421875	1.28	1.2814	0.72	206156	0.84646697	CS
12	-1.295	-59.9537037037	2.16	2.16	0.72	129627	1.14946669	CS
26	-1.365	-61.2107623318	2.23	3.325	0.72	92450	1.52259286	CS
52	-3.015	-77.706185567	3.88	5.28	0.72	104936	2.53593013	CS
156	-3.725	-81.1546840959	4.59	8.82	0.72	121444	3.163661	CS
260	-5.085	-85.4621848739	5.95	8.82	0.72	143620	4.06766534	CS

ACXP - Frequently Asked Questions (FAQ)

What is the current Acurx Pharmaceuticals share price?

The current share price of Acurx Pharmaceuticals is US$ 0,865

How many Acurx Pharmaceuticals shares are in issue?

Acurx Pharmaceuticals has 16 892 548 shares in issue

What is the market cap of Acurx Pharmaceuticals?

The market capitalisation of Acurx Pharmaceuticals is USD 15,1M

What is the 1 year trading range for Acurx Pharmaceuticals share price?

Acurx Pharmaceuticals has traded in the range of US$ 0,72 to US$ 5,28 during the past year

What is the PE ratio of Acurx Pharmaceuticals?

The price to earnings ratio of Acurx Pharmaceuticals is -1

What is the reporting currency for Acurx Pharmaceuticals?

Acurx Pharmaceuticals reports financial results in USD

What is the latest annual profit for Acurx Pharmaceuticals?

The latest annual profit of Acurx Pharmaceuticals is USD -14,58M

What is the registered address of Acurx Pharmaceuticals?

The registered address for Acurx Pharmaceuticals is 251 LITTLE FALLS DRIVE, NEW CASTLE, WILMINGTON, DELAWARE, 19808

What is the Acurx Pharmaceuticals website address?

The website address for Acurx Pharmaceuticals is www.acurxpharma.com

Which industry sector does Acurx Pharmaceuticals operate in?

Acurx Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
NXUNXU Inc	US$ 1,4301 (487,55%)	385,81M
WATTEnergous Corporation	US$ 1,605 (290,32%)	159,58M
INTZIntrusion Inc	US$ 5,78 (167,59%)	109,65M
CYNCYNGN Inc	US$ 1,2697 (102,21%)	57,71M
HOLOMicroCloud Hologram Inc	US$ 4,47 (86,25%)	87,54M
ABPAbpro Holdings Inc	US$ 2,1699 (-51,67%)	1,32M
TRAWTraws Pharma Inc	US$ 7,595 (-43,41%)	879,38k
LITMSnow Lake Resources Ltd	US$ 1,0894 (-31,91%)	43,49M
LGHLWLion Group Holding Ltd	US$ 0,0052 (-25,71%)	54,74k
BITSGlobal X Blockchain and Bitcoin Stratagy ETF	US$ 66,81 (-24,48%)	8,74k
NXUNXU Inc	US$ 1,4494 (495,48%)	382,52M
VINCVincerx Inc	US$ 0,35 (80,41%)	290,62M
XTIAXTI Aerospace Inc	US$ 0,03995 (1,14%)	164,99M
WATTEnergous Corporation	US$ 1,61 (291,54%)	158,84M
SMXSMX Security Matters Public Company	US$ 0,6311 (78,48%)	111,03M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Acurx Pharmaceuticals Inc (ACXP) Cours

Acurx Pharmaceuticals Inc (ACXP)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de Acurx Pharmaceuticals Inc

ACXP Dernières nouvelles

ACXP - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application